📊 NTHI Key Takeaways
Is NTHI a Good Investment? Thesis Analysis
NTHI is a pre-revenue pharmaceutical company in severe financial distress with negative stockholders' equity of -$17.5M, indicating liabilities exceed assets. The company is burning cash at an unsustainable rate (-$20.9M FCF) with minimal revenue ($40K), no clear path to profitability, and a liquidity crisis evidenced by a 0.07x current ratio with only $58.7K in cash.
Why Buy NTHI? Key Strengths
- Operates in pharmaceutical sector with potential for high-margin products if clinical programs succeed
- Minimal revenue base suggests no legacy business constraints
- Long-term debt remains modest at $320K relative to the overall capital structure problem
NTHI Investment Risks to Consider
- Negative equity of -$17.5M creates existential solvency risk and likely insolvency
- Severe liquidity crisis with current ratio of 0.07x and only $58.7K cash against $20.3M liabilities
- Operating burn rate of -$20.4M annually is catastrophic and unsustainable without immediate capital infusion
- Revenue collapsed 51.8% YoY to only $40K, indicating complete lack of commercial traction
- Net margin of -155,404% and operating margin of -145,638% reflect fundamental business model failure
- Zero insider trading activity suggests lack of confidence from management in near-term prospects
Key Metrics to Watch
- Stockholders equity trend - critical for determining if company remains solvent
- Monthly cash burn rate and months of cash remaining
- Revenue generation and signs of clinical trial progression or partnership deals
- Capital raise announcements and dilution impact on existing shareholders
NTHI Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NTHI Profitability Ratios
NTHI vs Healthcare Sector
How NEONC TECHNOLOGIES HOLDINGS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NTHI Overvalued or Undervalued?
Based on fundamental analysis, NEONC TECHNOLOGIES HOLDINGS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NTHI Balance Sheet & Liquidity
NTHI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NEONC TECHNOLOGIES HOLDINGS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.69 indicates the company is currently unprofitable.
NTHI Growth Metrics (YoY)
NTHI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $40.0K | -$2.2M | $-0.12 |
| Q2 2025 | $20.0K | -$4.5M | $-0.27 |
| Q1 2025 | $40.0K | -$2.9M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NTHI Capital Allocation
NTHI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NEONC TECHNOLOGIES HOLDINGS, INC. (CIK: 0001979414)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NTHI
What is the AI rating for NTHI?
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NTHI's key strengths?
Claude: Operates in pharmaceutical sector with potential for high-margin products if clinical programs succeed. Minimal revenue base suggests no legacy business constraints.
What are the risks of investing in NTHI?
Claude: Negative equity of -$17.5M creates existential solvency risk and likely insolvency. Severe liquidity crisis with current ratio of 0.07x and only $58.7K cash against $20.3M liabilities.
What is NTHI's revenue and growth?
NEONC TECHNOLOGIES HOLDINGS, INC. reported revenue of $40.0K.
Does NTHI pay dividends?
NEONC TECHNOLOGIES HOLDINGS, INC. does not currently pay dividends.
Where can I find NTHI SEC filings?
Official SEC filings for NEONC TECHNOLOGIES HOLDINGS, INC. (CIK: 0001979414) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NTHI's EPS?
NEONC TECHNOLOGIES HOLDINGS, INC. has a diluted EPS of $-3.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NTHI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NEONC TECHNOLOGIES HOLDINGS, INC. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NTHI stock overvalued or undervalued?
Valuation metrics for NTHI: ROE of N/A (sector avg: 15%), net margin of -155,404.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NTHI stock in 2026?
Our dual AI analysis gives NEONC TECHNOLOGIES HOLDINGS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NTHI's free cash flow?
NEONC TECHNOLOGIES HOLDINGS, INC.'s operating cash flow is $-20.4M, with capital expenditures of $500.0K. FCF margin is -52,172.9%.
How does NTHI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -155,404.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 2).